Skip to content


  • Meeting abstract
  • Open Access

Simultaneously double infection of oncolytic viruses leads to addition of cell death induction in glioblastoma cell lines

  • 1,
  • 1,
  • 2 and
  • 1
Molecular and Cellular Pediatrics20152 (Suppl 1) :A28

  • Published:


  • Cell Death
  • Glioma Cell
  • Propidium Iodide
  • Annexin Versus
  • Glioblastoma Cell Line

Meeting abstract

Malignant glioblastomas are highly aggressive tumors virtually resistant to available treatments and predominantly leading to death. The standard treatment is surgical resection followed by chemo-irradiation therapy. However, the tumor always gains resistance after initial response. An improvement of outcome seems only be possible by evaluating new and innovative therapeutic strategies. An approach that has gained much interest for cancer treatment in the last years is virotherapy with oncolytic viruses. They represent a new class of anticancer therapeutics that have the ability to kill different forms of tumor cells. For three of such viruses (Reovirus, RV; Parvovirus-H, PV and Newcastle-Disease-Virus, NDV) a strong tumorlytic effect on glioma cells is described in vitro and in animal models [1]. It is known that the viruses can induce different kinds of cell death, like apoptosis or necroptosis, via different pathways [24].

To investigate the oncolytic capacity and the induction of cell death of RV, PV and NDV the glioblastoma cell line U87 was simultaneously infected with two viruses followed by analysis of cell survival by MTT-assay and the type of cell death by FACS staining for Annexin V and Propidium iodide. Moreover the cells were stained for virus proteins to search for double infection.

We could show that in simultaneously double infected cells, while the oncolytic effect of the stronger virus will be dominant, both viruses do induce the virus specific cell death. These effects are completely complementing each other. Furthermore we could show that the viruses can replicate at the same time in the cells.

Therefore we conclude that the use of two or more oncolytic viruses in glioblastoma therapy is a promising tool to add to the traditional therapy.

Authors’ Affiliations

Department for pediatric oncology and hematology, University of Saarland School of Medicine, 66421 Homburg, Germany
Department of Virology, University of Saarland School of Medicine, 66421 Homburg, Germany


  1. Wollmann G, Ozduman K, van den Pol AN: Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 2012,18(1):69–81. 10.1097/PPO.0b013e31824671c9PubMed CentralPubMedView ArticleGoogle Scholar
  2. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, et al.: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994,54(23):6017–6021.PubMedGoogle Scholar
  3. Herrero YCM, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K: Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 2004,109(1):76–84. 10.1002/ijc.11626View ArticleGoogle Scholar
  4. Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA: Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 2011,117(8):1764–1174. 10.1002/cncr.25741PubMedView ArticleGoogle Scholar


© Ehrhardt et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.